O

Onesource Specialty Pharma Ltd
NSE:ONESOURCE

Watchlist Manager
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Watchlist
Price: 1 334.1 INR 1.37% Market Closed
Market Cap: ₹152.9B

Onesource Specialty Pharma Ltd
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Onesource Specialty Pharma Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
O
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Note Receivable
₹1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Note Receivable
₹1.3B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
1%
A
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Note Receivable
₹316.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sai Life Sciences Ltd
NSE:SAILIFE
Note Receivable
₹124m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
Anthem Biosciences Ltd
NSE:ANTHEM
Note Receivable
₹100.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Onesource Specialty Pharma Ltd
Glance View

Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.

ONESOURCE Intrinsic Value
1 109.24 INR
Overvaluation 17%
Intrinsic Value
Price
O

See Also

What is Onesource Specialty Pharma Ltd's Note Receivable?
Note Receivable
1B INR

Based on the financial report for Mar 31, 2025, Onesource Specialty Pharma Ltd's Note Receivable amounts to 1B INR.

What is Onesource Specialty Pharma Ltd's Note Receivable growth rate?
Note Receivable CAGR 1Y
41%

Over the last year, the Note Receivable growth was 41%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett